What is a PCSK9 inhibitor?

A PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor is a medication that helps lower LDL cholesterol levels in the blood. These inhibitors work by targeting the PCSK9 protein, which regulates the levels of LDL receptors in the liver. By inhibiting PCSK9, more LDL receptors are available to remove LDL cholesterol from the bloodstream.

How does enlicitide decanoate work as a PCSK9 inhibitor?

Enlicitide decanoate is a novel oral macrocyclic peptide designed to bind to PCSK9,preventing it from interacting with LDL receptors. This action increases the number of LDL receptors available to clear LDL cholesterol, effectively lowering cholesterol levels in patients with hyperlipidemia.

What are the potential benefits of an oral PCSK9 inhibitor like enlicitide decanoate?

An oral PCSK9 inhibitor offers a more convenient governance route compared to the currently available injectable PCSK9 inhibitors. This can improve patient compliance and make it easier for individuals with hyperlipidemia to manage their cholesterol levels daily.

Who is enlicitide decanoate intended for?

Enlicitide decanoate is intended for adults with hyperlipidemia, including those with heterozygous familial hypercholesterolemia (HeFH) and those at risk for atherosclerotic cardiovascular disease (ASCVD). It is designed to be used in conjunction with statins or other cholesterol-lowering therapies.

What were the main findings of the CORALreef clinical trials?

The CORALreef HeFH and coralreef AddOn trials demonstrated that enlicitide decanoate induced statistically significant and clinically meaningful reductions in LDL cholesterol. the trials also showed that enlicitide decanoate had greater reductions in LDL-C compared to placebo and other oral non-statin therapies, with no clinically meaningful differences in adverse events.

Why is lowering LDL cholesterol critically important?

lowering LDL cholesterol is crucial for reducing the risk of atherosclerotic cardiovascular events, such as heart attacks and strokes.LDL-C is a major modifiable risk factor for atherosclerosis, and effective management of LDL-C levels is a cornerstone of cardiovascular risk prevention.

Health

Enlicitide Decanoate: Major LDL-C Reduction in New Study

by Dr. Michael Lee – Health Editor June 14, 2025

written by Dr. Michael Lee – Health Editor June 14, 2025

“`html

Oral PCSK9 Inhibitor Enlicitide Decanoate Shows Promise in Lowering

Share this:
Facebook
X

Related

pharmacy times

Dr. Michael Lee – Health Editor

Dr. Michael Lee – Health Editor Dr. Michael Lee is a physician, medical writer, and Health Editor for World Today News. He translates complex health topics into clear, practical advice and leads our coverage of medical breakthroughs, public health, and wellness.

Enlicitide Decanoate: Major LDL-C Reduction in New Study

Oral PCSK9 Inhibitor Enlicitide Decanoate Shows Promise in Lowering Share this: Click to share on Facebook (Opens in new window) Facebook Click to share on X (Opens in new window) X Related pharmacy times

Share this:

Related

Trump’s Iran Stance Splits His Base: ‘Drop Israel’ Debate

Booking.com: AI’s Impact on Developer Productivity – A Data Deep Dive

You may also like

Leave a Comment Cancel Reply

Oral PCSK9 Inhibitor Enlicitide Decanoate Shows Promise in Lowering

Share this:
Facebook
X

Related

pharmacy times